Rezolute (RZLT) News Today $4.53 -0.10 (-2.16%) Closing price 04:00 PM EasternExtended Trading$4.70 +0.18 (+3.86%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Wladimir Hogenhuis Purchases 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockRezolute, Inc. (NASDAQ:RZLT - Get Free Report) Director Wladimir Hogenhuis purchased 10,000 shares of Rezolute stock in a transaction on Tuesday, February 18th. The shares were acquired at an average cost of $4.70 per share, for a total transaction of $47,000.00. Following the purchase, the director now owns 77,267 shares in the company, valued at approximately $363,154.90. This trade represents a 14.87 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.February 21 at 8:51 PM | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis Acquires 10,000 SharesFebruary 21 at 7:09 AM | insidertrades.comHC Wainwright Predicts Rezolute's Q1 Earnings (NASDAQ:RZLT)February 18 at 2:39 AM | americanbankingnews.comRezolute: Late-Stage Study Targeting HyperinsulinismFebruary 18 at 2:02 AM | seekingalpha.comRezolute's SWOT analysis: biotech stock advances on ersodetug trialsFebruary 17, 2025 | msn.comWhat is Wedbush's Estimate for Rezolute FY2029 Earnings?Rezolute, Inc. (NASDAQ:RZLT - Free Report) - Research analysts at Wedbush upped their FY2029 earnings per share (EPS) estimates for shares of Rezolute in a research note issued on Thursday, February 13th. Wedbush analyst Y. Zhong now forecasts that the company will earn $0.46 per share for the yeFebruary 17, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for Rezolute Q1 Earnings?Rezolute, Inc. (NASDAQ:RZLT - Free Report) - HC Wainwright issued their Q1 2026 EPS estimates for shares of Rezolute in a research note issued to investors on Thursday, February 13th. HC Wainwright analyst D. Tsao expects that the company will post earnings per share of ($0.33) for the quarter. HFebruary 17, 2025 | marketbeat.comShort Interest in Rezolute, Inc. (NASDAQ:RZLT) Expands By 17.4%Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) was the recipient of a large growth in short interest in January. As of January 31st, there was short interest totalling 1,620,000 shares, a growth of 17.4% from the January 15th total of 1,380,000 shares. Based on an average daily volume of 455,400 shares, the days-to-cover ratio is currently 3.6 days.February 16, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Rezolute (NASDAQ:RZLT)February 15, 2025 | americanbankingnews.comRezolute’s Strategic Advances in Rare Disease TherapiesFebruary 14, 2025 | tipranks.comRezolute, Inc. (NASDAQ:RZLT) Receives Average Rating of "Buy" from AnalystsFebruary 14, 2025 | americanbankingnews.comRezolute to announce DMC conclusions in April, says H.C. WainwrightFebruary 14, 2025 | markets.businessinsider.comRezolute's (RZLT) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $14.00 price objective on shares of Rezolute in a research report on Thursday.February 13, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Given New $9.00 Price Target at JMP SecuritiesJMP Securities raised their target price on shares of Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a research note on Thursday.February 13, 2025 | marketbeat.comJMP Securities lifts Rezolute stock target to $9, maintains ratingFebruary 13, 2025 | msn.comRezolute price target raised to $9 from $8 at JMP SecuritiesFebruary 13, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Crispr Therapeutics AG (CRSP)February 13, 2025 | markets.businessinsider.comRezolute reports Q2 EPS (22c), consensus (26c)February 12, 2025 | markets.businessinsider.comRezolute (NASDAQ:RZLT) Releases Earnings Results, Beats Expectations By $0.11 EPSRezolute (NASDAQ:RZLT - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.11.February 12, 2025 | marketbeat.comRezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business UpdateFebruary 12, 2025 | globenewswire.comRezolute (NASDAQ:RZLT) Earns Buy Rating from GuggenheimFebruary 11, 2025 | americanbankingnews.comRezolute Insiders Placed Bullish Bets Worth US$557.5kFebruary 11, 2025 | finance.yahoo.comRezolute (NASDAQ:RZLT) Receives "Buy" Rating from GuggenheimGuggenheim reaffirmed a "buy" rating on shares of Rezolute in a report on Monday.February 10, 2025 | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Receives Consensus Recommendation of "Buy" from AnalystsShares of Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) have been assigned an average rating of "Buy" from the eight analysts that are currently covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating toFebruary 9, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Rating Increased to Strong-Buy at Craig HallumCraig Hallum raised shares of Rezolute to a "strong-buy" rating in a research report on Tuesday.February 6, 2025 | marketbeat.comH.C. Wainwright reiterates Buy on Rezolute shares, $14 targetFebruary 6, 2025 | msn.comRezolute's (RZLT) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $14.00 price objective on shares of Rezolute in a report on Wednesday.February 5, 2025 | marketbeat.comRezolute, Inc.: Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital HyperinsulinismFebruary 4, 2025 | finanznachrichten.deRezolute's ersodetug advances in pediatric studyFebruary 4, 2025 | msn.comRezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital HyperinsulinismFebruary 4, 2025 | globenewswire.comRezolute (RZLT) Projected to Post Earnings on TuesdayRezolute (NASDAQ:RZLT) will be releasing earnings before the market opens on Tuesday, February 11, Financial Modeling Prep reports.February 4, 2025 | marketbeat.comRezolute to Participate in the Guggenheim SMID Cap Biotech ConferenceJanuary 31, 2025 | globenewswire.comCantor Fitzgerald Estimates Rezolute FY2025 EarningsRezolute, Inc. (NASDAQ:RZLT - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Rezolute in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings of ($0.97) per shareJanuary 23, 2025 | marketbeat.comOptimistic Outlook on Rezolute’s RZ358 Clinical Progress Fuels Buy RatingJanuary 18, 2025 | markets.businessinsider.comRezolute, Inc. (NASDAQ:RZLT) Given Consensus Recommendation of "Buy" by AnalystsShares of Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) have been assigned a consensus rating of "Buy" from the eight analysts that are presently covering the stock, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating. The average twelve-month price objectiJanuary 15, 2025 | marketbeat.comGeode Capital Management LLC Buys 137,905 Shares of Rezolute, Inc. (NASDAQ:RZLT)Geode Capital Management LLC raised its stake in Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 39.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 491,601 shares of the company's stock after acquiring an additionaJanuary 8, 2025 | marketbeat.comRezolute’s Promising Developments in Hyperinsulinism Treatments Justify Buy RatingJanuary 7, 2025 | markets.businessinsider.comRezolute receives BTD from FDA for ersodetug in treatment of hypoglycemiaJanuary 7, 2025 | markets.businessinsider.comRezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital HyperinsulinismJanuary 7, 2025 | finance.yahoo.comDaron Evans Buys 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockDecember 19, 2024 | insidertrades.comInsider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 10,000 Shares of StockRezolute, Inc. (NASDAQ:RZLT - Get Free Report) CFO Daron Evans purchased 10,000 shares of the company's stock in a transaction that occurred on Wednesday, December 18th. The stock was purchased at an average price of $4.29 per share, for a total transaction of $42,900.00. Following the purchase, the chief financial officer now owns 150,900 shares in the company, valued at $647,361. This represents a 7.10 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.December 18, 2024 | marketbeat.comInsider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Acquires 9,000 Shares of StockDecember 13, 2024 | insidertrades.comRezolute’s Erodsetug: A Promising Universal Treatment for Severe Refractory Hypoglycemia with Strong Growth PotentialDecember 5, 2024 | markets.businessinsider.comRezolute reports inducement award under Nasdaq listing ruleDecember 5, 2024 | markets.businessinsider.comRezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)December 5, 2024 | globenewswire.comRezolute announces U.S. FDA granted ODD to ersodetugDecember 3, 2024 | markets.businessinsider.comRezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism MarketDecember 3, 2024 | seekingalpha.comFDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor HyperinsulinismDecember 3, 2024 | markets.businessinsider.comRezolute's Ersodetug Gets Orphan Drug Designation To Treat Hypoglycemia Due To Tumor HyperinsulinismDecember 3, 2024 | markets.businessinsider.comRezolute, Inc. Advances Late-Stage Trials for Rare Disease TherapiesNovember 26, 2024 | markets.businessinsider.com Get Rezolute News Delivered to You Automatically Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter. Email Address RZLT Media Mentions By Week RZLT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RZLT News Sentiment▼1.010.60▲Average Medical News Sentiment RZLT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RZLT Articles This Week▼163▲RZLT Articles Average Week Get Rezolute News Delivered to You Automatically Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRVI News ELVN News PAHC News ZYME News ABCL News REPL News COLL News RCKT News EOLS News PHVS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RZLT) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rezolute With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
